Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma.
about
Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing.European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention.Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.Mobilization characteristics and strategies to improve hematopoietic progenitor cell mobilization and collection in patients with chronic granulomatous disease and severe combined immunodeficiencyHematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.Autologous stem cell transplantation beyond 60 years of age.Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: practical issues.Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.Optimal time to start peripheral blood stem cell collection in children with high-risk solid tumors.A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation.Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs.Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.The evolving role of plerixafor in hematopoietic progenitor cell mobilization.Advances in stem cell mobilization.A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program.Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean mulHow do we mobilize and collect autologous peripheral blood stem cells?The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells.Intermediate doses of cytarabine plus granulocyte-colony-stimulating factor as an effective and safe regimen for hematopoietic stem cell collection in lymphoma patients with prior mobilization failure.Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma.Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo OsseoEngraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients.Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT.Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis.Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly.Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.A novel hematopoietic progenitor cell mobilization and collection algorithm based on preemptive CD34 enumeration.Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN).Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-fThe addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF
P2860
Q27692619-D2AD44CF-BC5B-4644-82EE-77D922C19E34Q34073741-97EFFA69-AF6C-47B0-99AB-9C0398CDCDCFQ34432943-51316B70-67B3-4C49-ADB2-6FF207FDB935Q34490998-B0B370B6-2F80-473C-8ADC-61E22ED6738AQ34971081-1241985E-2559-4890-B5D2-D8624B65424DQ35091493-642818D0-5A92-42D2-92D6-3D0428E4EBCDQ36428104-C7846317-AA80-4EA7-9DC1-C238F0D0DC48Q36623644-2BDC8AF9-ECB8-4BD5-9734-D9F05F11DD67Q37053190-3E2628BA-82EE-4C18-8844-A6AB6629F649Q37424430-F73A05D4-AEC6-4E91-909E-E4E162A003D2Q37473582-6437BC7B-39A2-4AE5-81E1-B31EA8DF7B19Q37738995-CB80276D-6563-47DB-B08F-5F3E3EB9AF49Q37785509-DB68F186-898B-4785-964D-EAF186DFC6C8Q37943423-222733F6-AF97-4930-8B44-104EAE0C469BQ38077807-DE248C01-0E4B-437B-960C-EC131474E9B6Q38183225-9A7A29BA-343E-445C-83A3-5F71CF385D83Q38194916-98557FE4-A575-4751-838E-85A8DD236953Q38418369-A94016C5-124D-4731-BFCF-9E24371DA8DCQ38978669-AFA0479C-F4D1-4B39-8868-B11F6731519BQ39049318-DE88D32B-6B3A-4C12-8DDC-0856A21F76EAQ41685138-7387C197-4389-481A-B9BF-49880BA20858Q41969982-5D1803F8-9105-44F6-9D4C-F64721F1F21CQ42592824-74198721-E8F7-41B7-A969-943A30C45543Q43524297-E30754C4-290F-4483-BD7C-EAC23D42FDB3Q44256421-23C43395-9E66-4D0E-AC16-BBB1ABE4FD9DQ44736591-30545F59-B4E0-4DE2-AE1F-98FB85B0BE58Q45000707-866E02C9-A7C6-40F5-AA9A-07E5892EBBA9Q45763455-1841F2FB-D449-4373-A7AD-6D13753DCCD0Q46925369-99DCC182-80AE-4492-B5FA-0E3A309D8F0EQ47696715-9304DB98-1954-48FA-A79E-5F1E5483ADA9Q49852695-259E19A9-24A2-4D40-AB51-239AE08E70F3Q50942920-9468E58A-7AE2-447C-9C28-9F33F88DB699Q51450235-68484B62-6A40-4094-9AEC-B8E99E038876Q51680781-6493D037-D681-448B-8250-2F2A82A524E3Q51705517-C481279F-C6A8-45A3-90FD-CAD5E492E917Q51776428-F2909FB9-BE1A-427D-9134-E1EE20294A79Q52658547-B37CB08E-9A44-4502-905C-A9A691EE54AFQ53262189-79933F73-EDBF-495F-8363-8790FD844818Q56986459-BE427790-C030-4129-A4A2-18475C38C36D
P2860
Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma.
@en
Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma.
@nl
type
label
Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma.
@en
Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma.
@nl
prefLabel
Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma.
@en
Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma.
@nl
P2093
P2860
P356
P1476
Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma.
@en
P2093
Jantunen E
Kuittinen T
Mahlamäki E
Nousiainen T
P2860
P2888
P304
P356
10.1038/SJ.BMT.1704466
P407
P577
2004-05-01T00:00:00Z